Hyperimmunized egg product for treatment or prevention of coronavirus infection

Inventors

Iyer, Subramanian V. • Chandrasekhar, Satishchandran • Saxena, Uday • KADIYALA, Gopi

Assignees

Kyntox Biotech India Pvt Ltd • Reagene Biosciences Pvt Ltd • Lay Sciences Inc • Prodigy Biotech Inc

Abstract

In one aspect, the present disclosure is directed to a method for preventing or treating a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a hyperimmunized egg product obtained from an egg-producing animal, thereby preventing or treating coronavirus infection in the subject, wherein the hyperimmunized egg product comprises a therapeutically effective amount of one or more antibodies to the coronavirus. The present disclosure is also directed to hyperimmunized eggs and egg products produced by an animal that has been hyperimmunized with an antigen selected from i) a spike (S) protein, an S1 subunit protein, an S2 subunit protein, a receptor binding domain (RBD), and an immunogenic fragment thereof; ii) a nucleocapsid (N) protein, and an immunogenic fragment thereof; iii) a human ACE2 receptor protein, and an immunogenic fragment thereof; and iv) a human coronavirus selected from the group consisting of SARS-CoV, MERS-CoV, SARS-CoV-2, HCoV-HKU1, HCoV-NL63, HCoV-OC43 and HCoV-229E. Methods of preparing the hyperimmunized eggs and egg products are also disclosed.

Core Innovation

The invention relates to treating or preventing coronavirus infection by administering a therapeutically effective amount of a hyperimmunized egg product containing coronavirus-specific antibodies. The hyperimmunized egg product is prepared from whole egg, yolk, or a purified IgY fraction obtained from hyperimmunized eggs.

Hyperimmunization is performed in an egg-producing animal with a composition comprising coronavirus antigens, including SARS-CoV, MERS-CoV, and SARS-CoV-2. The antigens include spike protein (S), S1/S2, the receptor binding domain (RBD), immunogenic fragments, nucleocapsid (N), and human ACE2 receptor, and may be combined with an optional adjuvant.

The method includes preparing the hyperimmunized egg product by dehydrating, spray drying, or freeze drying the whole egg, yolk, or purified IgY fraction from the hyperimmunized eggs. The resulting product may be provided as nanoparticles or microparticles and may further be encapsulated using encapsulating material and one selected encapsulation process.

Claims Coverage

1 independent claim (clm-00001) is directed to a method of preparing a hyperimmunized egg product. The claim set includes multiple dependent refinements that mainly add particle size constraints and encapsulation/formulation options.

The claims cover preparing a hyperimmunized egg product by hyperimmunizing an egg-producing animal with an antigen defined by SEQ ID NO: 19, then producing the product by dehydrating, spray drying, or freeze drying whole egg, yolk, or purified IgY. Dependent claim coverage further specifies nanoparticle and microparticle product forms and adds encapsulation using selected encapsulation processes.

Stated Advantages

Documented Applications